CCRM
Alex Cruz has an extensive background in finance and accounting, with experience as a Director & Controller at CCRM, Controller at Dalton Pharma Services, Viventia Bio Inc., and Cytochroma Inc., Corporate Controller at OPKO Renal Division, and various other roles in finance and accounting at Angiotech. Alex holds a Bachelor's degree in Economics and has completed education with CGA Canada and Santa Clara University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.